3,5-Diiodothyropropionic acid
Based on 1 publication(s) in Google Scholar
3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M-1 for TRα1 and TRβ1, respectively. 3,5-Diiodothyropropionic acid promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay. 3,5-Diiodothyropropionic acid prevents myocardial arteriolar loss in thyroidectomized rats and enhances cardiac energy-generating capacity in postinfarction heart failure rats. 3,5-Diiodothyropropionic can be used in studies related to angiogenesis and heart failure.
For research use only. We do not sell to patients.
- Purity: 98.34%
- CAS No.: 1158-10-7
- Formula: C15H12I2O4
- Molecular Weight:510.06
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endocrinology Compound Library
HY-L047
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) 3,5-Diiodothyropropionic acid
More
Biological Activity
3,5-Diiodothyropropionic acid (0.1 μM) promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay, with 2.1-fold increase in migrated cells and 2.0-fold increase in microvessel length [4].
3,5-Diiodothyropropionic acid (0.1 mM, 3 days) stimulates angiogenesis in 10-day-old chick embryo chorioallantoic membrane[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
3,5-Diiodothyropropionic acid (375 μg/100 g, subcutaneous injection, once daily, 10 days) improves energy-generating capacity of the heart, and returns most downregulated metabolic genes toward normal in postinfarction heart failure rats[3].
3,5-Diiodothyropropionic acid (375 μg/100 g, subcutaneous injection once daily for 10 days, with Captopril (HY-B0368) 2 g/L in drinking water for 21 days) improves cardiac energy-generating capacity, and returns more genes toward normal compared to used alone in postinfarction heart failure rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Thyroidectomized male Sprague-Dawley rats (10.5 weeks old)[2]
-
Dosage:80 mg/60-day release pellets
-
Administration:Via subcutaneous slow-release pellets for 6 weeks
-
Result:Prevented a 31% reduction in myocardial arteriolar length density in thyroidectomized Sprague-Dawley rats, with the 5-15 μm arterioles well preserved.
Failed to prevent hypothyroidism-induced decreases in body temperature, body weight gain, heart weight and heart weight-to-body weight ratio.
Did not improve cardiac function parameters including posterior wall thickness, fractional shortening, +dP/dt, -dP/dt, and heart rate.
Increased serum triiodothyronine (T3) levels but kept serum thyroxine (T4) levels as low as the placebo group.
-
Animal Model:Adult male Spraque-Dawley rats (175-275 g) were anesthetized with methoxyflurane, subjected to left thoracotomy, and a ligature was placed around the proximal left coronary artery to induce myocardial infarction[3]
-
Dosage:375 μg/100 g
-
Administration:Subcutaneous injection once daily for 10 days
-
Result:Reversed the downregulation of most metabolic genes.
Restored the energy-generating capacity of the heart.
Improved cardiac function as evidenced by reduced left ventricular end-diastolic pressure.
-
Animal Model:Adult male Spraque-Dawley rats (175-275 g) were anesthetized with methoxyflurane, subjected to left thoracotomy, and a ligature was placed around the proximal left coronary artery to induce myocardial infarction [3]
-
Dosage:375 μg/100 g
-
Administration:Subcutaneous injection once daily for 10 days, with Captopril (HY-B0368) 2 g/L in drinking water for 21 days
-
Result:Reversed the downregulation of metabolic enzymes.
Restored the energy-generating capacity of the heart.
Improved cardiac function as evidenced by more genes returning toward normal compared to used alone.
Chemical Information
-
CAS No. 1158-10-7
-
Appearance Solid
-
Molecular Weight 510.06
-
Formula C15H12I2O4
-
Color White to off-white
-
SMILES
O=C(O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Environ Sci Technol
IodoFinder: Machine Learning-Guided Recognition of Iodinated Chemicals in Nontargeted LC-MS/MS Analysis. [Abstract]2025 Mar 11;59(9):4530-4539. PMID: 40015982
Solvent & Solubility
DMSO : 50 mg/mL (98.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pennock GD, et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992 Oct;263(1):163-9. [Content Brief]
[2]. Liu Y, et al. Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1551-7. [Content Brief]
[3]. Maitra N, et al. Regulation of gene expression in rats with heart failure treated with the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) and the combination of DITPA and captopril. J Cardiovasc Pharmacol. 2007 Nov;50(5):526-34. [Content Brief]
[4]. Mousa SA, et al. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology. 2006 Apr;147(4):1602-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9606 mL | 9.8028 mL | 19.6055 mL | 49.0138 mL |
| 5 mM | 0.3921 mL | 1.9606 mL | 3.9211 mL | 9.8028 mL | |
| 10 mM | 0.1961 mL | 0.9803 mL | 1.9606 mL | 4.9014 mL | |
| 15 mM | 0.1307 mL | 0.6535 mL | 1.3070 mL | 3.2676 mL | |
| 20 mM | 0.0980 mL | 0.4901 mL | 0.9803 mL | 2.4507 mL | |
| 25 mM | 0.0784 mL | 0.3921 mL | 0.7842 mL | 1.9606 mL | |
| 30 mM | 0.0654 mL | 0.3268 mL | 0.6535 mL | 1.6338 mL | |
| 40 mM | 0.0490 mL | 0.2451 mL | 0.4901 mL | 1.2253 mL | |
| 50 mM | 0.0392 mL | 0.1961 mL | 0.3921 mL | 0.9803 mL | |
| 60 mM | 0.0327 mL | 0.1634 mL | 0.3268 mL | 0.8169 mL | |
| 80 mM | 0.0245 mL | 0.1225 mL | 0.2451 mL | 0.6127 mL |
3,5-Diiodothyropropionic acid Related Classifications
HY-126236 Related Classifications
Powered by Bioz